



CanaQuest Medical Corp – Introduction

"Mentanine® is the only formula that addresses mental health ailments by enabling CBD to penetrate the Brain - no other CBD product can"

CanaQuest (OTC: CANQF) is a publicly traded Life Science/Pharmaceutical Company developing proprietary Medical products utilizing cannabinoid molecules and other pharmaceutical grade botanical compounds for the treatment of numerous mental health issues.

Our vision:

- To be a **global leader** in the formulation and development of health products from cannabis derivatives.
- Our two Master Formulations, IP Protected, enable us to target identified rare diseases and multiple ailments.
- Our business model, with an exceptionally low burn rate, positions our company to contract manufacture and sell our formulated products anywhere in the world in accordance with regulations.

CanaQuest Proprietary Products:

- **Mentanine®** - Omega-3/CBD Formula. Pre-clinical trials **highlighted advantages over** every CBD product on the market today, including FDA-approved Epidiolex. (Provisional Patent filed). Preclinical trials have shown that Mentanine® has **~10x efficacy** compared to Epidiolex. Mentanine® is delivered sublingually and bypasses the digestive system and liver, unlike any other product on the market.
- **Mentabinol®** - THC isolate/L-Theanine formula, is **the only** safer alternative medication to any THC product on the market, including FDA-approved Sativex. (International Patent filed).

Highlights:

- Mentanine®, CanaQuest's scientifically developed formulation, is designed to follow the same regulatory pathway as **GW Pharmaceuticals Plc.** Epidiolex, CBD-based medication approved by the FDA, generated first year revenue of \$290 Million.
- CanaQuest's Subsidiary, **ADC BioMedical Corp**, was awarded a Health Canada licence to sell, import and export cannabis and cannabinoid products for Medical purposes.
- The Company has initiated the process to obtain approval for a Drug Identification Number "DIN" from Health Canada and pursue FDA-approval in the US (seek Orphan Drug Status – FDA approval expected in under 1 year).
- CanaQuest won the **Go Global Awards (2019) "Business of the Year – Category of Life Science,"** presented by the **International Trade Council.**

www.canaqueststore.com e-commerce site will be ready to sell products to Canadian-based registered patients in January.

Management:

Our co-founders previously founded and built Cymat Technologies, which was listed on the TSE with a valuation greater than **\$150M** when they resigned. Collectively, CanaQuest's team has more than 150 years of experience in management, product development, processing, and commercialization. We are currently developing our Scientific and Marketing Advisory Boards.

Science:

The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist, and his 13-member scientific team at Western University, London, Ontario, Canada. Dr. Laviolette's research has been featured in the Journal of Neuroscience.